Navigation Links
Treatment of Breast Cancer with Herceptin for Nine Weeks

A novel approach in the treatment of breast cancer is the new nine week course of Herceptin which also prevents the risk of heart problems.//

Herceptin is a monoclonal antibody that attacks the HER-2 protein that is highly expressed in about 30% of the breast cancers.

The results of the combination therapy (Herceptin + anthracycline-based chemotherapy) were better when compared to chemo alone.

A study was conducted by Finland researchers to analyze the safety and efficiency of Herceptin in 1010 women who had breast cancer. The women included in the study received docetaxel or vinorelbine and then FEC (5-fluorouracil, epirubicin, cyclophosphamide).Those whose HER-2 protein were increased Herceptin was given for nine weeks or no Herceptin was given.

After 3 years the results were reported as 91% of patients who received docetaxel were free of cancer recurrence when compared to 86% patients who received vinorelbine.

89% of the patients who received Herceptin were free of cancer recurrence when compared to 78% who did not receive Herceptin.

The survival rate also was longer in patients who received Herceptin and no increase in heart problems.

Hence it was concluded that the nine week Herceptin therapy along with docetaxel diminishes recurrence of cancer and prevents risk of heart problems. But further research is still being done on one year Herceptin therapy to study the efficacy of the therapy.
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage ... featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex ... cotton easy care stretch twill. , With trendy looks hitting the medical community, UA ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: